Login to Your Account

Adynxx Seeks to Silence Acute, Prevent Chronic Pain

By Marie Powers
Staff Writer

Wednesday, August 8, 2012

Fewer than five years after Adynxx Inc. was formed on the basis of "a great idea," the company disclosed that it moved lead compound AYX1 into the clinic, completing enrollment in a Phase I safety study in postoperative pain.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription